A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, and Herceptin in Patients With Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Lapatinib (Primary) ; Carboplatin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 21 Dec 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 06 Jun 2017 Planned End Date changed from 21 Dec 2017 to 31 Dec 2018.
- 06 Jun 2017 Planned primary completion date changed from 21 Dec 2017 to 31 Dec 2018.